📰 Genentech News
Page 144 - Genentech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.
June 16, 2023
The addition of gedatolisib to palbociclib and letrozole produced durable responses with comparable safety to that observed with palbociclib and letrozole alone in treatment-naïve patients with estrogen receptor-positive, HER2-negative advanced breast cancer.
June 16, 2023
- Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate, and a median duration of response of 1.5 years (18.4 months) - - Given over
June 16, 2023
Dublin, June 16, 2023 (GLOBE NEWSWIRE) -- The "Global Biosimilars Partnering Terms and Agreements 2010 to 2023" report has been added to ...
June 16, 2023
The FDA has approved glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy.
June 16, 2023
The drug is a T-cell-engaging bispecific antibody and has been approved for use in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
June 16, 2023
The US Food and Drug Administration (FDA) has approved the first bispecific antibody with a fixed-duration treatment in DLBCL.
June 16, 2023
Glofitamab targets CD3, a protein found on the surface of immune T cells in patients with relapsed or refractory diffuse large B-cell lymphoma, and CD20, a healthy or malignant protein that lines the surfaces of B cells.
June 16, 2023
Columvi is the first bispecific antibody that can be administered to patients with relapsed or refractory diffuse large B-cell lymphoma for a defined period of time.